Saniona AB: Saniona presents Tesomet Phase 2 data at the EASD Congress
(Thomson Reuters ONE) -
PRESS RELEASE
September 12, 2017
Saniona, a leading biotech company in the field of ion channels, today announces
that the promising data from its Phase 2a study with Tesomet in type 2 diabetes
has been selected for two poster presentations today at the European Association
for the Study of Diabetes, EASD congress 2017 taking place in Lisbon, Portugal.
"We were very pleased that the results from this promising study confirmed that
addition of metoprolol to tesofensine fully mitigates the increase in heart rate
and blood pressure previously observed with tesofensine. In addition, the data
showed a robust weight loss and reduction in waist circumference as well as
numerical reduction in liver fat in patients with type 2 diabetes coupled with a
favourable toleration and safety profile. Thus, these results, together with
data from previous clinical studies with tesofensine supports the use of Tesomet
as a safe and effective weight loss drug in patients with metabolic disorders
like diabetes and obesity. As a result, we have initiated the preparation for
long term clinical studies for metabolic diseases as well as eating disorders",
says Jørgen Drejer, CEO of Saniona.
Presentations
Poster #857 title: Co-administration of tesofensine/metoprolol: Improvement in
heart rate with significant body weight reduction in overweight or obese
subjects with type 2 diabetes
Session date: September 12, 2017, 12:00-13:00
Authors: Roman V. Dvorak(1), Grit Andersen(2), Berit Edsberg(1), Pavlína
Ka?parová(1), Jorge Arrubla(2), Leona Plum-Mörschel(3) ((1)Saniona A/S,
Ballerup, Denmark, (2)Profil, Neuss, Germany, (3)Profil, Mainz, Germany)
Presenter: Roman V. Dvorak
Poster #851 title: Co-administration of tesofensine/metoprolol: Improvements in
body weight and liver fat content in overweight or obese subjects with type 2
diabetes
Session date: September 12, 2017, 12:00-13:00
Authors: Grit Andersen(1), Tim Heise(1), Berit Edsberg(2), Daniela Lamers(1),
Thomas A. Jacobsen(2), Leona Plum-Mörschel(3), Roman V. Dvorak(2 )((1)Profil,
Neuss, Germany, (2)Saniona A/S, Ballerup, Denmark, (3)Profil, Mainz, Germany)
Presenter: Grit Andersen
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail:
tf(at)saniona.com
The information was submitted for publication, through the agency of the contact
person set out above, at 12:00 CET on September 12, 2017.
About Saniona
Saniona is a research and development company focused on drugs for diseases of
the central nervous system, autoimmune diseases, metabolic diseases and
treatment of pain. The company has a significant portfolio of potential drug
candidates at preclinical and clinical stage. The research is focused on ion
channels, which makes up a unique protein class that enables and controls the
passage of charged ions across cell membranes. Saniona has ongoing collaboration
agreements with Boehringer Ingelheim GmbH, Proximagen Ltd., Productos Medix,
S.bA de S.V and Luc Therapeutics Inc. Saniona is based in Copenhagen, Denmark,
where it has a research center of high international standard. Saniona is listed
at Nasdaq Stockholm Small Cap and has about 5,100 shareholders. The company's
share is traded under the ticker SANION. Read more at www.saniona.com.
Tesomet poster No 851 safety 20170912:
http://hugin.info/172499/R/2133177/815614.pdf
Tesomet poster No 857 efficacy 20170912:
http://hugin.info/172499/R/2133177/815615.pdf
20170912 - PR - Poster - UK:
http://hugin.info/172499/R/2133177/815613.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Saniona AB via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 12.09.2017 - 12:00 Uhr
Sprache: Deutsch
News-ID 559618
Anzahl Zeichen: 4363
contact information:
Town:
Ballerup
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 168 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Saniona AB: Saniona presents Tesomet Phase 2 data at the EASD Congress"
steht unter der journalistisch-redaktionellen Verantwortung von
Saniona AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
